At a glance
- Originator AstraZeneca
- Class Muscle relaxants
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Urinary incontinence
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for Urinary incontinence in USA (unspecified route)
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 07 Sep 1998 No-Development-Reported for Urinary incontinence in USA (unspecified route)